Specifically for Novocure, Tumor Treating Fields (TTFields) delivered by the NovoTTF-100ATTM System in combination with standard-of-care temozolomide chemotherapy was recently assessed in a Company sponsored phase III trial [EF-14] with 2:1 randomization. Interim analysis of the first 315 patients, representing approximately 50 percent of the targeted study population, was presented on November 15, 2014 at the Society for Neuro-Oncology Annual Meeting. The patients treated with TTF demonstrated a significant increase in progression free survival compared to temozolomide alone (median PFS of 7.1 months compared to 4.0 months, respectively, hazard ratio=0.63, p=0.001); and a significant increase in overall survival compared to temozolomide alone (median OS of 19.6 months compared to 16.6 months, respectively, hazard ratio=0.75, p=0.034).